Indefinite Delivery Contract SPE2DR25D9961

The federal contract IDV award SPE2DR25D9961 is a single-award Indefinite Delivery Contract (IDC) issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $499,999,999 IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide.

The original solicitation, expected to be issued in March 2024, will establish Pharmaceutical Prime Vendor Global Program Generation V contracts to provide worldwide pharmaceutical support to various Department of Defense (DoD) customers, including the Defense Health Agency, United States Coast Guard, and US Naval Fleet. The procurement, estimated at $30.3 billion, will be awarded on a regional basis to at least three different contractors for the North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet line items, as well as a separate award for a backup supplier. The contracts will have a 30-month base period and three 30-month option periods, with awards made to the responsive and responsible offerors whose proposals are technically acceptable and offer the lowest overall distribution fees.